Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Gliquidone

Gliquidone: A Targeted Approach to Type 2 Diabetes Management

Introduction

Type 2 diabetes mellitus (T2DM) has emerged as a global epidemic, affecting hundreds of millions of people worldwide. Characterized by insulin resistance and impaired insulin secretion, T2DM requires a multifaceted management strategy. Among the various oral hypoglycemic agents available, sulfonylureas play a significant role, especially in settings where cost-effective solutions are essential. Gliquidone, a second-generation sulfonylurea, is less known than its counterparts like glibenclamide or glipizide but has unique properties that make it particularly valuable in specific patient populations. 

Gliquidone

Overview

  • Drug Class: Sulfonylurea (second-generation)

  • Chemical Structure: Related to glibenclamide and glipizide

  • Primary Action: Stimulates insulin release from pancreatic beta cells

  • Route of Administration: Oral

  • Brand Names: Glurenorm (among others)

Gliquidone is primarily used for managing type 2 diabetes, especially in patients with mild to moderate hyperglycemia. It is not used for type 1 diabetes or diabetic ketoacidosis.

Mechanism of Action

Like other sulfonylureas, gliquidone binds to ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells. This binding causes:

  • Closure of potassium channels

  • Membrane depolarization

  • Opening of voltage-gated calcium channels

  • Influx of calcium ions

  • Exocytosis of insulin-containing granules

What distinguishes gliquidone from some other sulfonylureas is its hepatic metabolism, which makes it safer for use in patients with mild to moderate renal impairment.

Pharmacokinetics

Property Gliquidone
Bioavailability ~95%
Time to peak plasma concentration 1–2 hours
Half-life 1–3 hours
Metabolism Primarily hepatic
Excretion Mainly biliary (fecal); minimal renal excretion

This pharmacokinetic profile gives gliquidone a shorter duration of action, which allows for flexible dosing schedules and lowers the risk of prolonged hypoglycemia.

Clinical Uses

Primary Indication

  • Type 2 Diabetes Mellitus: As monotherapy or in combination with other antidiabetic agents when diet, exercise, and weight control are insufficient.

Special Utility

  • Elderly Patients

  • Patients with mild renal impairment

  • Patients needing short-acting hypoglycemic control

Due to its biliary elimination, gliquidone is less reliant on renal clearance, unlike other sulfonylureas, which makes it a safer choice in patients with chronic kidney disease (CKD) stages 2–3.

Dosing Recommendations

  • Initial Dose: 15 mg once daily before breakfast

  • Titration: Can be gradually increased up to a maximum of 120 mg/day, divided into 2–3 doses

  • Maintenance Dose: Typically ranges from 30–60 mg/day

  • Timing: Administered 30 minutes before meals to synchronize with postprandial glucose rise

Patients should be educated to not skip meals after taking gliquidone to reduce the risk of hypoglycemia.

Efficacy and Glycemic Control

Numerous clinical studies have shown that gliquidone:

  • Reduces fasting plasma glucose (FPG) by 25–40%

  • Decreases HbA1c by 1–2%

  • Offers glycemic control comparable to other sulfonylureas

  • Has a rapid onset and a short duration, making it ideal for meal-time glycemic regulation

It is especially effective in patients with residual beta-cell function and in the early stages of T2DM.

Benefits of Gliquidone

  1. Hepatic Clearance: Safer in renal impairment

  2. Short Half-Life: Lower risk of prolonged hypoglycemia

  3. Cost-Effective: Accessible in low-resource settings

  4. Flexible Dosing: Can be adjusted based on meal timing and blood glucose levels

  5. Well-Tolerated: Minimal gastrointestinal side effects compared to metformin

Side Effects

Common

  • Hypoglycemia (especially in elderly or those with irregular eating habits)

  • Weight gain

  • Headache

  • Dizziness

  • Nausea

Rare but Serious

  • Cholestatic jaundice

  • Blood dyscrasias (leukopenia, thrombocytopenia)

  • Allergic skin reactions

Due to its rapid action and shorter half-life, hypoglycemia episodes are usually mild and of shorter duration compared to longer-acting sulfonylureas.

Contraindications

  • Type 1 diabetes

  • Diabetic ketoacidosis

  • Severe liver dysfunction

  • Hypersensitivity to sulfonylureas

  • Pregnancy and breastfeeding

  • Severe renal failure (due to potential hepatic accumulation in end-stage renal disease)

Drug Interactions

Gliquidone may interact with:

  • NSAIDs and salicylates (increase hypoglycemia risk)

  • Beta-blockers (mask hypoglycemia symptoms)

  • Alcohol (enhances hypoglycemic effect)

  • Corticosteroids and diuretics (antagonize hypoglycemic effects)

  • Warfarin (potentiation of anticoagulant effect)

Patients should be advised to report all medications they are using, including over-the-counter and herbal products.

Monitoring Parameters

  • Fasting and postprandial blood glucose levels

  • HbA1c every 3–6 months

  • Liver function tests (if long-term use)

  • Signs and symptoms of hypoglycemia

  • Weight changes

Routine monitoring helps assess efficacy and prevent adverse effects like hypoglycemia and liver-related issues.

Use in Special Populations

Elderly

  • Start at the lowest effective dose

  • Monitor for signs of hypoglycemia

  • Adjust doses based on renal and hepatic function

Renal Impairment

  • Preferred over other sulfonylureas due to non-renal elimination

  • Still used with caution in severe renal dysfunction

Pregnancy and Breastfeeding

  • Contraindicated; insulin is the drug of choice

Comparing Gliquidone to Other Sulfonylureas

Feature Gliquidone Glibenclamide Glipizide Gliclazide
Half-life 1–3 hrs 10 hrs 2–4 hrs 10–12 hrs
Metabolism Hepatic Hepatic Hepatic Hepatic
Excretion Biliary Renal Renal Renal
Hypoglycemia Risk Moderate High Moderate Low
Renal Safety Preferred Avoid Caution Caution

Gliquidone is particularly advantageous in elderly diabetic patients with mild renal insufficiency where glibenclamide or glipizide could cause prolonged hypoglycemia.

Patient Education Tips

  • Take before meals; do not skip meals after taking the drug

  • Recognize signs of hypoglycemia: sweating, dizziness, palpitations, hunger

  • Always carry a source of sugar (e.g., glucose tablets)

  • Maintain a consistent carbohydrate intake

  • Inform healthcare providers about all current medications

  • Avoid alcohol or monitor closely if alcohol is consumed

Recent Research and Developments

While gliquidone is not as heavily studied as newer agents like GLP-1 agonists or SGLT2 inhibitors, its unique pharmacokinetic profile and renal safety continue to spark interest in specific clinical scenarios. Ongoing studies are exploring its potential as part of combination therapy regimens and its comparative effectiveness against newer agents in low- and middle-income countries.

Role in Current Guidelines

International diabetes management guidelines (ADA, IDF, WHO) do not prioritize gliquidone as a first-line agent, mainly due to the emergence of newer medications with cardiovascular and renal protective effects. However, gliquidone:

  • Remains a valuable second-line option after metformin

  • Is recommended in renal impairment when other sulfonylureas are unsuitable

  • Is still widely used in Europe, Asia, and Latin America

Conclusion

Gliquidone offers a well-balanced approach for managing type 2 diabetes in patients who require insulin secretagogues. With its short half-life, hepatic metabolism, and effective glucose-lowering capabilities, it fills a unique niche among sulfonylureas. It is especially suited for elderly patients, those with renal impairment, and individuals needing flexible, meal-time dosing. While it may not be in the spotlight alongside newer antidiabetic drugs, gliquidone's efficacy, safety profile, and affordability make it a relevant option in modern diabetes care—especially in settings where accessibility and cost are important considerations.